Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy

To see complete record on, please visit this link

Id: NCT04661514

Organisation Name: University of California, San Diego

Overal Status: Completed

Start Date: May 1, 2021

Last Update: July 25, 2022

Lead Sponsor: University of California, San Diego

Brief Summary: The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight.

  • Anorexia Nervosa

Total execution time in seconds: 0.32637786865234